The Endocrine Society has issued a clinical practice guideline on the endocrine treatment of gender-dysphoric/gender-incongruent persons, updating the 2009 guideline. The guideline emphasizes the importance of a multidisciplinary approach, with endocrinologists playing a key role in providing hormone therapy to align physical characteristics with the affirmed gender. Hormone treatment is not recommended for prepubertal children. For adolescents who have entered puberty, gonadotropin-releasing hormone (GnRH) agonists are recommended to suppress pubertal development, followed by gender-affirming hormones after a multidisciplinary team confirms the persistence of gender dysphoria and the individual's capacity to give informed consent. For adults, hormone therapy should be based on confirmed diagnosis and criteria for gender transition. The guideline also outlines the need for regular monitoring of hormone levels, bone density, cardiovascular risk factors, and other potential complications. It recommends that clinicians avoid hormone treatment for individuals without gender dysphoria who may not benefit from the physical changes. The guideline emphasizes the importance of informed consent, fertility preservation options, and collaboration between mental health professionals and endocrinologists. It also highlights the need for long-term follow-up and the importance of shared decision-making in treatment. The guideline is based on a systematic review of available evidence and includes recommendations for the management of transgender individuals across the lifespan. The guideline also addresses the importance of cultural sensitivity and the need for ongoing research to improve the understanding and treatment of gender dysphoria.The Endocrine Society has issued a clinical practice guideline on the endocrine treatment of gender-dysphoric/gender-incongruent persons, updating the 2009 guideline. The guideline emphasizes the importance of a multidisciplinary approach, with endocrinologists playing a key role in providing hormone therapy to align physical characteristics with the affirmed gender. Hormone treatment is not recommended for prepubertal children. For adolescents who have entered puberty, gonadotropin-releasing hormone (GnRH) agonists are recommended to suppress pubertal development, followed by gender-affirming hormones after a multidisciplinary team confirms the persistence of gender dysphoria and the individual's capacity to give informed consent. For adults, hormone therapy should be based on confirmed diagnosis and criteria for gender transition. The guideline also outlines the need for regular monitoring of hormone levels, bone density, cardiovascular risk factors, and other potential complications. It recommends that clinicians avoid hormone treatment for individuals without gender dysphoria who may not benefit from the physical changes. The guideline emphasizes the importance of informed consent, fertility preservation options, and collaboration between mental health professionals and endocrinologists. It also highlights the need for long-term follow-up and the importance of shared decision-making in treatment. The guideline is based on a systematic review of available evidence and includes recommendations for the management of transgender individuals across the lifespan. The guideline also addresses the importance of cultural sensitivity and the need for ongoing research to improve the understanding and treatment of gender dysphoria.